IMVTImmunovant, Inc.

Nasdaq immunovant.com


$ 29.56 $ 1.15 (4.05 %)    

Wednesday, 29-May-2024 15:59:55 EDT
QQQ $ 454.82 $ -3.24 (-0.7 %)
DIA $ 398.57 $ -4.02 (-1.03 %)
SPY $ 530.36 $ -3.71 (-0.7 %)
TLT $ 91.26 $ -1.09 (-1.21 %)
GLD $ 225.37 $ -2.03 (-0.93 %)
$ 29.57
$ 31.21
$ 0.00 x 0
$ 31.02 x 100
$ 29.54 - $ 31.77
$ 18.16 - $ 45.58
2,690,866
na
4.08B
$ 1.27
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-29-2024 03-31-2024 10-K
2 02-12-2024 12-31-2023 10-Q
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-22-2023 03-31-2023 10-K
6 02-03-2023 12-31-2022 10-Q
7 11-04-2022 09-30-2022 10-Q
8 08-05-2022 06-30-2022 10-Q
9 06-08-2022 03-31-2022 10-K
10 02-04-2022 12-31-2021 10-Q
11 11-05-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 06-01-2021 03-31-2021 10-K
14 02-16-2021 12-31-2020 10-Q
15 11-12-2020 09-30-2020 10-Q
16 08-12-2020 06-30-2020 10-Q
17 06-29-2020 03-31-2020 10-K
18 02-14-2020 12-31-2019 10-Q
19 11-13-2019 09-30-2019 10-Q
20 08-12-2019 06-30-2019 10-Q
21 06-12-2019 03-31-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 immunovant-q4-eps-052-misses-043-estimate

Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.43) ...

 biohaven-stock-stumbles-as-protein-degrading-drug-falls-short-of-expectations-in-early-stage-study

Biohaven shares drop as interim data from the Phase 1 study of BHV-1300 fell short of investor expectations.

 oppenheimer-initiates-coverage-on-immunovant-with-outperform-rating-announces-price-target-of-50

Oppenheimer analyst Leland Gershell initiates coverage on Immunovant (NASDAQ:IMVT) with a Outperform rating and announces Pr...

 truist-securities-reiterates-buy-on-immunovant-maintains-48-price-target

Truist Securities analyst Robyn Karnauskas reiterates Immunovant (NASDAQ:IMVT) with a Buy and maintains $48 price target.

 goldman-sachs-initiates-coverage-on-immunovant-with-buy-rating-announces-price-target-of-50

Goldman Sachs analyst Corinne Johnson initiates coverage on Immunovant (NASDAQ:IMVT) with a Buy rating and announces Price T...

 wolfe-research-initiates-coverage-on-immunovant-with-outperform-rating-announces-price-target-of-55

Wolfe Research analyst Andy Chen initiates coverage on Immunovant (NASDAQ:IMVT) with a Outperform rating and announces Price...

 recap-immunovant-q3-earnings
Recap: Immunovant Q3 Earnings
02/12/2024 13:00:06

 immunovant-q3-eps-036-up-from-049-yoy-cash-and-cash-equivalents-totaled-approximately-691m

Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.36) per share. This is a 26.53 percent increase over losses of $(0.49...

 why-carmax-shares-are-trading-higher-by-around-8-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings.

 b-of-a-securities-maintains-buy-on-immunovant-raises-price-target-to-51

B of A Securities analyst Jason Gerberry maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $49 ...

 autoimmune-disease-player-immunovants-investigational-drug-for-immune-system-disorder-shows-response-rates-of-over-50

Immunovant Inc (NASDAQ: IMVT), on Thursday, released the results from the initial cohort of patients in an ongoing 24-week Phas...

 amazoncom-to-rally-over-38-here-are-10-top-analyst-forecasts-for-thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 hc-wainwright--co-maintains-buy-on-immunovant-raises-price-target-to-51

HC Wainwright & Co. analyst Douglas Tsao maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from ...

 micron-posts-upbeat-sales-joins-calliditas-therapeutics-and-other-big-stocks-moving-higher-in-thursdays-pre-market-session

U.S. stock futures were higher this morning, with the Dow Jones futures gaining more than 150 points on Thursday.

Core News & Articles

Batoclimab was generally well tolerated with no new safety signals observed in the initial data set. 

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION